ARCHIVES

DePinho’s Letter to CPRIT’s Gimson, And Gimson’s Response

This article is from The Cancer Letter archive.

Vol. 38 No. 22 | June 1, 2012

Download PDF Visit The Full Archive

Related Articles

Funding Exceptions, Skipovers, While Limited At NCI, Become Crucial Issues; NCAB To Be Brief On Details

January 7, 1983

NeoRx Suspends Accrual, Treatment In Phase III trial Using STR For Myeloma.

December 1, 2000

Aromasin Approved By FDA For ER+ Early Breast Cancer

October 28, 2005

Non-Profit Spent $1.3 Million On Consultants.

March 28, 2008

Frozen Serum Panels Available For Assays

June 8, 1984

Shubik Warns NCA Members They May Be Prober’s Next Target

May 22, 1981